ReviewFrontiers in psychiatry2023
Psychedelic therapy in the treatment of addiction: the past, present and future.
Review in Frontiers in psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study.Journal of clinical psychopharmacologyTrial
- The effects of low-dose ketamine and (2R,6R)-Hydroxynorketamine on affective behaviors associated with protracted oxycodone withdrawal.Psychopharmacology · 2026Article
- A Missing Voice? Peer Support Workers' Perceptions of Psychedelic-Assisted Therapy in Australia: A Cross-Sectional Survey.Brain and behavior · 2026Article
- Cannabidiol as a treatment for cocaine use disorder: a scoping review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Opioid Receptors in Psychedelia: Indirect Serotonergic Modulation of Direct KOR Activation by Salvinorin A.Biomedicines · 2026Review
- Renewal and reacquisition of substance-associated relapse.Frontiers in psychology · 2026Review
- Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View.Molecular neurobiology · 2025Review
- Psychedelic 5-HTNature neuroscience · 2025Article
- A Systematic Review and Meta-Analysis Investigating the Efficacy of Various Psychedelic Drugs for the Treatment of Substance Use Disorder.Healthcare (Basel, Switzerland) · 2025Review
- The Research Deficit and Expert Disagreement Regarding Music Selection for Psychedelic Assisted Therapy.ACS pharmacology & translational science · 2025Article
- The Role of Psychedelics in Contemporary Psychological and Interdisciplinary Inquiry.Journal of personalized medicine · 2025Review
- Emerging Interventions in Behavioral Addictions: A Narrative Review of Psychedelics and Neuromodulation.Brain sciences · 2025Review
- Psychedelics and the Serotonin Hypothesis of Eating Disorders.Brain sciences · 2025Review
- "I've learned that I'm open-minded to this possibility": A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke.Addiction science & clinical practice · 2025Article
- Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings.Brain and behavior · 2025Article
- Gut Microbiome-Liver-Brain axis in Alcohol Use Disorder. The role of gut dysbiosis and stress in alcohol-related cognitive impairment progression: possible therapeutic approaches.Neurobiology of stress · 2025Article
- The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature.Expert opinion on pharmacotherapy · 2025Review
- Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies.Cellular and molecular life sciences : CMLS · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychedelic therapy has witnessed a resurgence in interest in the last decade from the scientific and medical communities with evidence now building for its safety and efficacy in treating a range of psychiatric disorders including addiction. In this review we will chart the research investigating the role of these interventions in individuals with addiction beginning with an overview of the current socioeconomic impact of addiction, treatment options, and outcomes. We will start by examining historical studies from the first psychedelic research era of the mid-late 1900s, followed by an overview of the available real-world evidence gathered from naturalistic, observational, and survey-based studies. We will then cover modern-day clinical trials of psychedelic therapies in addiction from first-in-human to phase II clinical trials. Finally, we will provide an overview of the different translational human neuropsychopharmacology techniques, including functional magnetic resonance imaging (fMRI) and positron emission tomography (PET), that can be applied to foster a mechanistic understanding of therapeutic mechanisms. A more granular understanding of the treatment effects of psychedelics will facilitate the optimisation of the psychedelic therapy drug development landscape, and ultimately improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.